SyntheticMR AB (publ)

SYNTH.TE has a current ratio of 2.09, indicating a moderate level of liquidity, but its operating cash flow is negative at -5.47 million SEK, suggesting ongoing cash flow challenges. The company's debt-to-equity ratio is 0.05, reflecting a low level of leverage, and its total liabilities are 31.7 million SEK compared to total assets of 137.6 million SEK. Despite this, the company's free cash flow is negative at -51.05 million SEK, indicating a significant outflow of cash after capital expenditures.

The company's profitability is weak, with a return on equity of -51.84% and a return on assets of -39.9%, both significantly below the industry median for the Advanced Medical Equipment & Technology sector. Gross profit is 6.26 million SEK on revenue of 57.05 million SEK, resulting in a gross margin of 10.97%, which is below the industry median for gross margin. The company's operating income is negative at -49.31 million SEK, indicating a substantial operating loss.

SYNTH.TE's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's revenue is entirely derived from its core healthcare equipment business, and there are no material revenue contributions from other segments or geographic regions.

The company's growth trajectory is negative, with a net income of -54.93 million SEK and an operating income of -49.31 million SEK. The company's capital expenditures are -7.93 million SEK, indicating ongoing investment in its operations, but this has not translated into positive cash flow or profitability. The company's revenue history shows a decline, and there are no indications of a turnaround in the near term.

SYNTH.TE faces significant risk factors, including a negative net cash position after subtracting total debt, which indicates liquidity risk. The company's dilution potential is low, with no recent issuance or shelf registration activity reported. However, the company's negative operating cash flow and free cash flow suggest a need for external financing, which could lead to future dilution. The company's risk assessment indicates a medium level of liquidity risk and a low level of dilution risk.

Recent events include the company's financial performance, which has been negative, with a net loss of 54.93 million SEK. There are no recent filings or transcripts indicating significant changes in the company's strategy or operations. The company's analyst estimates are uniformly neutral, with a mean recommendation of 3.00, indicating a hold rating.